Søgeresultater - Phillippe Cassier
- Showing 1 - 2 results of 2
-
1
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors af Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French, Sophie Cousin, Irene Braña, Phillippe Cassier, Víctor Moreno, Johann S. de Bono, Sara Harward, Geraldine Ferron‐Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J. Parr, Rabinder Prinjha, Christopher L. Carpenter, John Hilton, David S. Hong, Naomi B. Haas, Mark C. Markowski, Arindam Dhar, Peter J. O’Dwyer, Geoffrey I. Shapiro
Udgivet 2019Artigo -
2
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors af Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho
Udgivet 2023Artigo
Søgeredskaber:
Relaterede emner
Internal medicine
Medicine
Acetylation
Adverse effect
Antibody
Atezolizumab
Biochemistry
Biology
Bromodomain
Cancer
Cancer research
Clinical endpoint
Clinical trial
Engineering
Gene
Immunology
Immunotherapy
Nut
Oncology
Pembrolizumab
Phases of clinical research
Structural engineering
TIGIT
Tolerability